Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution

References

• ParrishRK2ndFeuerWJSchiffmanJCLichterPRMuschDCCIGTS Optic Disc Study GroupFive-year follow-up optic disc findings of the Collaborative Initial Glaucoma Treatment StudyAm J Ophthalmol20091474717724.e119152871
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 Discussion 829–83012049574
   PubMed Web of Science ®Google Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• LeskeMCConnellAMWuSYHymanLSchachatAPDistribution of intraocular pressure. The Barbados Eye StudyArch Ophthalmol19971158105110579258228
   PubMedGoogle Scholar
• QuigleyHAEngerCKatzJSommerAScottRGilbertDRisk factors for the development of glaucomatous visual field loss in ocular hypertensionArch Ophthalmol199411256446498185522
   PubMed Web of Science ®Google Scholar
• ThamYCLiXWongTYQuigleyHAAungTChengCYGlobal prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysisOphthalmology2014121112081209024974815
   PubMed Web of Science ®Google Scholar
• No authors listedComparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study GroupAm J Ophthalmol199812644874979780093
   PubMed Web of Science ®Google Scholar
• AndersonDRNormal Tension Glaucoma StudyCollaborative normal tension glaucoma studyCurr Opin Ophthalmol2003142869012698048
   PubMedGoogle Scholar
• MuschDCGillespieBWLichterPRNiziolLMJanzNKCIGTS Study InvestigatorsVisual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factorsOphthalmology2009116220020719019444
   PubMed Web of Science ®Google Scholar
• No authors listedThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS InvestigatorsAm J Ophthalmol2000130442944011024415
   PubMed Web of Science ®Google Scholar
• PrumBEJrRosenbergLFGeddeSJPrimary open-angle glaucoma preferred practice pattern((R)) guidelinesOphthalmology20161231P41P11126581556
   PubMed Web of Science ®Google Scholar
• WeinrebRNAungTMedeirosFAThe pathophysiology and treatment of glaucoma: a reviewJAMA2014311181901191124825645
   PubMed Web of Science ®Google Scholar
• AlexanderCLMillerSJAbelSRProstaglandin analog treatment of glaucoma and ocular hypertensionAnn Pharmacother200236350451111895065
   PubMed Web of Science ®Google Scholar
• PatilAJVajaranantTSEdwardDPBimatoprost – a reviewExpert Opin Pharmacother200910162759276819874254
   PubMed Web of Science ®Google Scholar
• DaviesSSJuWKNeufeldAHAbranDChemtobSRobertsLJ2ndHydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitroJ Ocul Pharmacol Ther2003191455412648303
   PubMed Web of Science ®Google Scholar
• EisenbergDLTorisCBCamrasCBBimatoprost and travoprost: a review of recent studies of two new glaucoma drugsSurv Ophthalmol200247suppl 1S105S11512204706
   PubMed Web of Science ®Google Scholar
• HellbergMRKeTLHaggardKKlimkoPGDeanTRGraffGThe hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissueJ Ocul Pharmacol Ther20031929710312804054
   PubMed Web of Science ®Google Scholar
• MaxeyKMJohnsonJLLaBrecqueJThe hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonistSurv Ophthalmol200247suppl 1S34S4012204699
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHWangJWIdentification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline irisBr J Pharmacol2007150334235217179945
   PubMed Web of Science ®Google Scholar
• KraussAHWoodwardDFUpdate on the mechanism of action of bimatoprost: a review and discussion of new evidenceSurv Ophthal-mol200449suppl 1S5S11
   PubMed Web of Science ®Google Scholar
• WoodwardDFKraussAHChenJPharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024)J Pharmacol Exp Ther2003305277278512606640
   PubMed Web of Science ®Google Scholar
• CamrasCBTorisCBSjoquistBDetection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgeryOphthalmology2004111122193219815582073
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJWudunnDLevels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataractBr J Ophthalmol200791562963217135335
   PubMed Web of Science ®Google Scholar
• ChristiansenGANauCBMcLarenJWJohnsonDHMechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucomaOphthalmology200411191658166215350319
   PubMed Web of Science ®Google Scholar
• BrubakerRFSchoffEONauCBCarpenterSPChenKVandenburghAMEffects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAm J Ophthalmol20011311192411162974
   PubMed Web of Science ®Google Scholar
• JohnsonTVGuptaPKVudathalaDKBlairIATannaAPThermal stability of bimatoprost, latanoprost, and travoprost under simulated daily useJ Ocul Pharmacol Ther2011271515921117945
   PubMed Web of Science ®Google Scholar
• BrandtJDVanDenburghAMChenKWhitcupSMBimatoprost Study GroupComparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trialOphthalmology2001108610231031 Discussion 103211382623
   PubMed Web of Science ®Google Scholar
• DuBinerHCookeDDirksMStewartWCVanDenburghAMFelixCEfficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprostSurv Ophthalmol200145suppl 4S353S36011434938
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKVanDenburghAMBimatoprost Study GroupThree-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• LaibovitzRAVanDenburghAMFelixCComparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma managementArch Ophthalmol20011197994100011448321
   PubMedGoogle Scholar
• SherwoodMBrandtJBimatoprost Study GroupSix-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressureSurv Ophthalmol200145suppl 4S361S36811434939
   PubMed Web of Science ®Google Scholar
• NoeckerRSDirksMSChoplinNTA six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucomaAm J Ophthalmol20031351556312504698
   PubMed Web of Science ®Google Scholar
• SimmonsSTDirksMSNoeckerRJBimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trialsAdv Ther200421424726215605619
   PubMed Web of Science ®Google Scholar
• DirksMSNoeckerRJEarlMRohSSilversteinSMWilliamsRDA 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucomaAdv Ther200623338539416912020
   PubMed Web of Science ®Google Scholar
• MyersJSVoldSZamanFWilliamsJMHollanderDABimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trialsClin Ophthalmol2014864365224707169
   PubMedGoogle Scholar
• KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661.e661671.e66120346780
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration CfDEaRLumigan NDA 22-184 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022184Orig1s000SumR.pdfAccessed February 11, 2017
   Google Scholar
• BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• GheithMEMayerJRSiamGAMonteiro de BarrosDSThomasTLKatzLJManaging refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)Clin Ophthalmol200821152019668385
   PubMedGoogle Scholar
• GoldbergIGil PinaRLanzagorta-ArestiASchiffmanRMLiuCBejanianMBimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trialBr J Ophthalmol201498792693124667994
   PubMed Web of Science ®Google Scholar
• KurtzSMannOIncidence of hyperemia associated with bimatoprost treatment in naive subjects and in subjects previously treated with latanoprostEur J Ophthalmol200919340040319396785
   PubMed Web of Science ®Google Scholar
• HonrubiaFGarcia-SanchezJPoloVde la CasaJMSotoJConjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trialsBr J Ophthalmol200993331632119019922
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• TrattlerWNoeckerRJEarlMLA multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertensionAdv Ther200825317918918351298
   PubMed Web of Science ®Google Scholar
• CravenERLiuCCBatoosinghASchiffmanRMWhitcupSMA randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostClin Ophthalmol201041433144021188155
   PubMedGoogle Scholar
• LealBCMedeirosFAMedeirosFWSantoRMSusannaRJrConjunctival hyperemia associated with bimatoprost use: a histopathologic studyAm J Ophthalmol2004138231031315289152
   PubMed Web of Science ®Google Scholar
• AstinMStjernschantzJSelenGRole of nitric oxide in PGF2 alpha-induced ocular hyperemiaExp Eye Res19945944014077532135
   PubMed Web of Science ®Google Scholar
• JohnstoneMAHypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprostAm J Ophthalmol199712445445479323945
   PubMed Web of Science ®Google Scholar
• GiannicoATLimaLRussHHMontiani-FerreiraFEyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbitsJ Ocul Pharmacol Ther201329981782023981234
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIOne-year, random-ized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol2002120101286129312365906
   PubMed Web of Science ®Google Scholar
• TauchiMFuchsTAKellenbergerAJWoodwardDFPausRLutjen-DrecollECharacterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprostBr J Dermatol201016261186119720346040
   PubMed Web of Science ®Google Scholar
• WistrandPJStjernschantzJOlssonKThe incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye colorSurv Ophthalmol199741suppl 2S129S1389154289
   PubMed Web of Science ®Google Scholar
• StjernschantzJWAlbertDMHuDNDragoFWistrandPJMechanism and clinical significance of prostaglandin-induced iris pigmentationSurv Ophthalmol200247suppl 1S162S17512204714
   PubMed Web of Science ®Google Scholar
• SharpeEDReynoldsACSkutaGLJenkinsJNStewartWCThe clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapyCurr Eye Res200732121037104318085467
   PubMed Web of Science ®Google Scholar
• KapurROsmanovicSToyranSEdwardDPBimatoprost-induced periocular skin hyperpigmentation: histopathological studyArch Ophthalmol2005123111541154616286616
   PubMedGoogle Scholar
• DoshiMEdwardDPOsmanovicSClinical course of bimatoprost-induced periocular skin changes in CaucasiansOphthalmology2006113111961196716935336
   PubMed Web of Science ®Google Scholar
• FilippopoulosTPaulaJSTorunNHattonMPPasqualeLRGrosskreutzCLPeriorbital changes associated with topical bimato-prostOphthal Plast Reconstr Surg2008244302307
   PubMed Web of Science ®Google Scholar
• ParkJChoHKMoonJIChanges to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprostJpn J Ophthalmol2011551222721331688
   PubMed Web of Science ®Google Scholar
• KucukevciliogluMBayerAUysalYAltinsoyHIProstaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprostClin Exp Ophthalmol201442212613123844550
   PubMed Web of Science ®Google Scholar
• AiharaMShiratoSSakataRIncidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprostJpn J Ophthalmol201155660060421953485
   PubMed Web of Science ®Google Scholar
• SakataRShiratoSMiyataKAiharaMRecovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprostJpn J Ophthalmol201357217918423233196
   PubMed Web of Science ®Google Scholar
• SarnoffDSGotkinRHBimatoprost-induced chemical blepharoplastyJ Drugs Dermatol201514547247725942665
   PubMed Web of Science ®Google Scholar
• FechtnerRDKhouriASZimmermanTJAnterior uveitis associated with latanoprostAm J Ophthalmol1998126137419683147
   PubMed Web of Science ®Google Scholar
• SmithSLPruittCASineCSHudginsACStewartWCLatanoprost 0.005% and anterior segment uveitisActa Ophthalmol Scand199977666867210634560
   PubMedGoogle Scholar
• PackerMFineIHHoffmanRSBilateral nongranulomatous anterior uveitis associated with bimatoprostJ Cataract Refract Surg200329112242224314670442
   PubMed Web of Science ®Google Scholar
• FortunaECervantes-CastanedaRABhatPDoctorPFosterCSFlare-up rates with bimatoprost therapy in uveitic glaucomaAm J Ophthalmol2008146687688219027422
   PubMed Web of Science ®Google Scholar
• ChangJHMcCluskeyPMissottenTFerrantePJalaludinBLightmanSUse of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?Br J Ophthalmol200892791692118460537
   PubMed Web of Science ®Google Scholar
• SchumerRACamrasCBMandahlAKLatanoprost and cystoid macular edema: is there a causal relation?Curr Opin Ophthalmol20001129410010848227
   PubMedGoogle Scholar
• WandMGaudioARShieldsMBLatanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyesJ Cataract Refract Surg20012791397140111566522
   PubMed Web of Science ®Google Scholar
• AyyalaRSCruzDAMargoCECystoid macular edema associated with latanoprost in aphakic and pseudophakic eyesAm J Ophthalmol199812646026049780112
   PubMed Web of Science ®Google Scholar
• ChengJWWeiRLMeta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressureClin Ther200830462263218498911
   PubMed Web of Science ®Google Scholar
• HorsleyMBChenTCThe use of prostaglandin analogs in the uveitic patientSemin Ophthalmol2011264–528528921958176
   PubMed Web of Science ®Google Scholar
• SunLLWelchRTVuPLower eyelid melanoma during bimatoprost (Lumigan) therapyClin Exp Ophthalmol201240221321422004163
   PubMed Web of Science ®Google Scholar
• TresslerCSWisemanRLDombiTMLack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literatureBr J Ophthalmol201195111490149521515566
   PubMed Web of Science ®Google Scholar
• GrimesPEBimatoprost 0.03% solution for the treatment of nonfacial vitiligoJ Drugs Dermatol201615670371027272076
   PubMed Web of Science ®Google Scholar
• ZaherHGawdatHIHegazyRAHassanMBimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: a pilot studyDermatology2015230430831325765294
   PubMed Web of Science ®Google Scholar
• OkekeCOQuigleyHAJampelHDAdherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid studyOphthalmology2009116219119919084273
   PubMed Web of Science ®Google Scholar
• LewisRAChristieWCDayDGBimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trialAm J Ophthalmol201717513714728012819
   PubMed Web of Science ®Google Scholar
• BrandtJDSallKDuBinerHSix-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled studyOphthalmology201612381685169427157843
   PubMed Web of Science ®Google Scholar